PhD student at Zagazig University, Egypt
Ahmed Sobhy Abdelrahim Abdallah Darwish is an accomplished analytical chemist and Laboratories Development Deputy Manager at Egyptian International Pharmaceutical Industries (EIPICO), also affiliated with Zagazig University. He holds a B.Sc. in Chemistry‑Physics, a diploma (Analytical Chemistry, excellent), pre-master, and a Master’s degree, all from Zagazig University. Currently pursuing a Ph.D. He began his career in QC laboratories at Delta Pharma, then progressed through section head roles at Grand Pharma, Averroes, Al‑Debeiky, and Copad Pharma. He leads a team of ten at EIPICO, overseeing method development, stress stability studies, and comparative in vitro investigations. He actively contributes to regulatory harmonization by engaging with USP, BP, SFDA, and other pharmacopoeias. A Best Researcher Award recipient, he has submitted case studies to BP and participated in USP pilot programs. He also serves as a peer reviewer for international journals.
Professional Profile
Google Scholar | ORCID
Education
Ahmed Sobhy Darwish’s academic background showcases a steady commitment to excellence in analytical chemistry. He began his studies with a Bachelor’s degree in Chemistry‑Physics from Zagazig University, graduating with high distinction. He further pursued a diploma in Analytical Chemistry with top honors, followed by a pre‑master qualification marked by outstanding academic achievement. His educational journey culminated in a Master’s degree in Analytical Chemistry, and he is currently engaged in doctoral studies in the same field. His English proficiency is evidenced by a TOEFL score that surpasses common requirements for doctoral programs. This well-structured academic progression illustrates his deepening expertise, strong theoretical foundation, and dedication to advanced analytical techniques.
Professional Experience
Research Focus
Dr. Darwish’s research centers on developing eco-friendly, stability-indicating HPLC and liquid chromatography methods for pharmaceutical analysis. His work prioritizes environmental sustainability while ensuring robustness and regulatory compliance. Key areas include quantifying drugs such as piracetam, vincamine, levomenol, netilmicin, colchicine, khellin, valsartan, sacubitril, simvastatin, and fenofibrate in bulk and finished dosage forms. He emphasizes certified reference materials, green solvent systems, and minimal waste generation. By submitting two eco-analytical case studies to the British Pharmacopoeia sustainability guidance, he directly impacts regulatory practice. Participation in the USP Quality Assist Beta Pilot Program and BP Beta Site studies further reinforces his focus on method validation in real-world settings. His research bridges analytical precision with environmental responsibility, positioning him at the forefront of sustainable pharmaceutical quality control.
Publication Top Notes
“A Simple Eco‑Friendly Stability‑Indicating HPLC Method for Determination of NETILMICIN in Bulk and Ophthalmic Solution”, Biomedical Chromatography (August 2025), DOI: 10.1002/bmc.70152.
A validated HPLC approach using green solvents to quantify netilmicin in bulk and ophthalmic solutions, offering reduced environmental impact while maintaining assay accuracy.
“Environmental sustainability profiles assessment of HPLC stability indicating method for quantitation of piracetam and vincamine in pharmaceutical medications”, Talanta Open (August 2025), DOI: 10.1016/j.talo.2025.100407.
Evaluates environmental metrics (e.g., solvent consumption, waste) for HPLC methods analyzing piracetam and vincamine, demonstrating greener alternatives without sacrificing sensitivity.
“Developing a sensitive, ecological, and economic HPLC method for the concurrent quantification of KOLCHICINE and KHELLIN”, Microchemical Journal (July 30, 2025), DOI: 10.1016/j.microc.2025.114716.
Introduces a dual-analyte HPLC method for colchicine and khellin in bulk and sachets, optimized for sensitivity and cost-effectiveness using eco-friendly solvents.
“Simple validated approach to quantify valsartan and sacubitril in medications using liquid chromatography”, Bulletin of Faculty of Science, Zagazig University (July 1, 2025).
Presents a streamlined LC protocol for simultaneous determination of valsartan and sacubitril, validated for pharmaceutical formulations with robust linearity and accuracy.
“DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP‑HPLC METHOD FOR SIMULTANEOUS DETERMINATION OF SIMVASTATIN AND FENOFIBRATE IN BULK AND DOSAGE FORM”, Bulletin of Faculty of Science, Zagazig University (July 1, 2025).
Reports a reversed‑phase HPLC technique validated for concurrent analysis of simvastatin and fenofibrate, incorporating stress degradation studies to ensure specificity.
“An ecologically sound HPLC determination of LEVOMENOL in topical therapies using a certified reference material with green properties”, Results in Chemistry (May 8, 2025).
Describes a certified‑reference based HPLC method for levomenol quantification in topical products, optimizing green solvent usage while achieving regulatory-grade precision.